The indication for sacituzumab govitecan, also known as trodelvy, in bladder cancer is being withdrawn due to a lack of survival benefit. This decision follows a negative trial, and it will result in fewer treatment options for bladder cancer patients. The withdrawal of the drug's approval status is expected to have implications for patient care and treatment.